Skip to content

BICARA THERAPEUTICS INC.

BCAX

CIK 0002023658

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$156.78M
−102.9% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.78
+37.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$107.11M
Q1 May 2026
Cash
$323.46M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
65.7M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings